Published in Cardiovascular Device Liability Week, September 19th, 2004
Nurel Therapeutics is a specialty biotechnology company developing products to treat and manage pain and peripheral nerve damage, and is expanding into vascular disease. The company's products use a proprietary drug-delivery technology derived from an "inert" herpes simplex virus that provides gene-based medicine in a safe and effective manner.
"Nurel has raised some initial funds to help develop our first product candidate, NPE1, a treatment for chronic pain that has a potential market of $1 billion in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.